Reuters logo
BRIEF-Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product
February 21, 2017 / 2:05 PM / 10 months ago

BRIEF-Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product

Feb 21 (Reuters) - Valeant

* Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product in post-operative pain and inflammation in ocular surgery patients

* Valeant - EyeGate received an upfront cash payment and has potential to receive certain development-based milestone payments

* EyeGate received an upfront cash payment and has potential to receive certain development-based milestone payments

* Valeant - EyeGate will receive royalties on Valeant’s net sales of product

* Additionally, EyeGate will receive royalties on Valeant’s net sales of product

* Valeant - Valeant has right to further develop product outside of U.S., at its cost

* Says EyeGate will be responsible for continued development of EyeGate II delivery system in U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below